In addition, a tailored affibody molecule was built to mimic the structure of monoclonal antibody, which was confirmed with specificity to target HER2.437 With the additional intercalation of DOX, this DNA-affibody-drug chimera showed excellent specificity and inhibition to HER2-overexpressed cancer cells. Here, ERBB2 is linked to cancer.